Literature DB >> 28041631

Targeting fibroblast growth factor pathways in endometrial cancer.

Boris Winterhoff1, Gottfried E Konecny2.   

Abstract

Novel treatments that improve outcomes for patients with recurrent or metastatic endometrial cancer (EC) remain an unmet need. Aberrant signaling by fibroblast growth factors (FGFs) and FGF receptors (FGFRs) has been implicated in several human cancers. Activating mutations in FGFR2 have been found in up to 16% of ECs, suggesting an opportunity for targeted therapy. This review summarizes the role of the FGF pathway in angiogenesis and EC, and provides an overview of FGFR-targeted therapies under clinical development for the treatment of EC.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Endometrial cancer; Fibroblast growth factor

Mesh：

Substances：

Year:  2016        PMID： 28041631     DOI： 10.1016/j.currproblcancer.2016.11.002

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


  12 in total

1.  Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.

Authors:  Michihiro Mori; Toshinori Mori; Aina Yamamoto; Shoji Takagi; Masatsugu Ueda
Journal:  Hum Cell       Date:  2019-04-08       Impact factor: 4.174

Review 2.  Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer.

Authors:  Fengjun Guo; Haina Zhang; Zanhui Jia; Manhua Cui; Jingyan Tian
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

3.  Design, construction and in vivo functional assessment of a hinge truncated sFLT01.

Authors:  Fahimeh Zakeri; Hamid Latifi-Navid; Zahra-Soheila Soheili; Mehdi Sadeghi; Seyed Shahriar Arab; Shahram Samiei; Ehsan Ranaei Pirmardan; Sepideh Taghizadeh; Hamid Ahmadieh; Ali Hafezi-Moghadam
Journal:  Gene Ther       Date:  2022-09-16       Impact factor: 4.184

4.  Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.

Authors:  Frank Hilberg; Ulrike Tontsch-Grunt; Anke Baum; Anh T Le; Robert C Doebele; Simone Lieb; Davide Gianni; Tilman Voss; Pilar Garin-Chesa; Christian Haslinger; Norbert Kraut
Journal:  J Pharmacol Exp Ther       Date:  2017-12-20       Impact factor: 4.030

5.  Genomic landscape of advanced endometrial cancer analyzed by targeted next-generation sequencing and the cancer genome atlas (TCGA) dataset.

Authors:  Jin Hwa Hong; Hyun Woong Cho; Yung-Taek Ouh; Jae Kwan Lee; Yikyeong Chun; Jeong-An Gim
Journal:  J Gynecol Oncol       Date:  2022-01-24       Impact factor: 4.756

Review 6.  Not Only Immune Escape-The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis.

Authors:  Iwona Kwiatkowska; Justyna Magdalena Hermanowicz; Alicja Przybyszewska-Podstawka; Dariusz Pawlak
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

7.  Fibroblast Growth Factor (FGF) Signaling Protects Against Acute Pancreatitis-Induced Damage by Modulating Inflammatory Responses.

Authors:  Hai-Jian Tu; Cheng-Fei Zhao; Zhi-Wei Chen; Wei Lin; Yu-Cai Jiang
Journal:  Med Sci Monit       Date:  2020-04-13

8.  Establishment of the Prognosis Predicting Signature for Endometrial Cancer Patient.

Authors:  Jia Tang; Wei Ma; Liangping Luo
Journal:  Med Sci Monit       Date:  2019-11-03

9.  Importance of Translational Research for Targeting Fibroblast Growth Factor Receptor Signaling in Cancer.

Authors:  Klaus Holzmann; Brigitte Marian
Journal:  Cells       Date:  2019-10-02       Impact factor: 6.600

10.  A clear cancer cell line (150057) derived from human endometrial carcinoma harbors two novel mutations.

Authors:  Yu-Hsun Chang; Dah-Ching Ding
Journal:  BMC Cancer       Date:  2020-11-03       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.